NCT00424645 - Voraxaze for Delayed Methotrexate Clearance | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Hematologic MalignancySolid Tumor

Interventions

DRUG

Voraxaze (Glucarpidase)

50 units/kg IV within 12 hours of study eligibility being confirmed.

DRUG

Placebo

Administered by IV within 12 hours of study eligibility being confirmed.

Trial Locations (1)

U.T. M.D. Anderson Cancer Center, Houston